HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progress.

AbstractBACKGROUND:
Whereas many new targets for drug discovery have been identified from new biology, such as that from the Human Genome Project, some targets have been known for decades but have not been exploited.
OBJECTIVE:
One such target, selective thyromimetics, is reviewed from a historical perspective and in the light of recent developments.
METHODS:
The history of thyromimetics in atherosclerosis and dyslipidaemia is reviewed as the background to the recent publication of the first human data on a new selective thyromimetic, KB-2115 (eprotirome).
CONCLUSION:
The published data provide proof of concept/mechanism, opening the way to larger studies in a wider range of subjects and in combination with statins.
AuthorsKeith Suckling
JournalExpert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 17 Issue 5 Pg. 615-8 (May 2008) ISSN: 1744-7658 [Electronic] England
PMID18447589 (Publication Type: Editorial)
Chemical References
  • 3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid
  • Anilides
  • Thyroid Hormones
Topics
  • Anilides (chemistry, pharmacology, therapeutic use)
  • Atherosclerosis (drug therapy)
  • Drug Design
  • Dyslipidemias (drug therapy)
  • Humans
  • Molecular Structure
  • Thyroid Hormones (chemistry, pharmacology, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: